IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, will conduct a 1-for-30 reverse stock split on August 27, 2026. This move aims to increase its share price, currently at $0.11, to meet the Nasdaq Capital Market's minimum bid price requirement of $1.00. The reverse split consolidates shares without changing the total value of investors' holdings, helping the company maintain its Nasdaq listing. The company's market cap is about $345,570, with shares having traded between $0.09 and $2.61 over the past year.
Buckle, Inc. reported strong Q2 earnings with an EPS of $0.87, surpassing analyst estimates of $0.81, and revenue of $319.82 million, slightly above expectations. The company saw a 4.6% increase in net sales, driven by growth in both comparable-store...
KE Holdings Inc. reported Q2 2026 earnings with an EPS of $0.42, surpassing the $0.31 consensus estimate. Although revenue declined 5.7% year-over-year to about $3.60 billion, the company doubled its net income thanks to effective cost controls and o...
Structure Therapeutics (GPCR) maintains a Buy rating after its oral GLP-1 drug aleniglipron showed up to 16.2% weight loss in Phase 2b trials targeting obesity. The drug demonstrated a favorable safety profile and is now in Phase 3, with pivotal data...
Scott+Scott Attorneys at Law has filed a securities class action lawsuit against Aevex Corp., its directors, officers, and IPO underwriters. The suit alleges that they made false and misleading statements about a pre-arranged plan to waive the 180-da...
Synopsys reported strong Q2 results with a 5.96% EPS beat and 42% revenue growth, raising its full-year 2026 guidance. The company benefits from growing AI-driven demand in semiconductor design automation, expanding margins, and significant debt redu...
